BACKGROUND: Current clinical guidelines recommend earlier, more intensive breast cancer screening with both magnetic resonance imaging (MRI) and mammography for women with breast cancer susceptibility gene (BRCA) mutations. Unspecified details of screening schedules are a challenge for implementing guidelines. METHODS: A Markov Monte Carlo computer model was used to simulate screening in asymptomatic women who were BRCA1 and BRCA2 mutation carriers. Three dual-modality strategies were compared with digital mammography (DM) alone: 1) DM and MRI alternating at 6-month intervals beginning at age 25 years (Alt25), 2) annual MRI beginning at age 25 years with alternating DM added at age 30 years (MRI25/Alt30), and 3) DM and MRI alternating at 6-month intervals beginning at age 30 years (Alt30). Primary outcomes were quality-adjusted life years (QALYs), lifetime costs (in 2010 US dollars), and incremental cost-effectiveness (dollars per QALY gained). Additional outcomes included potential harms of screening, and lifetime costs stratified into component categories (screening and diagnosis, treatment, mortality, and patient time costs). RESULTS: All 3 dual-modality screening strategies increased QALYs and costs. Alt30 screening had the lowest incremental costs per additional QALY gained (BRCA1, $74,200 per QALY; BRCA2, $215,700 per QALY). False-positive test results increased substantially with dual-modality screening and occurred more frequently in BRCA2 carriers. Downstream savings in both breast cancer treatment and mortality costs were outweighed by increases in up-front screening and diagnosis costs. The results were influenced most by estimates of breast cancer risk and MRI costs. CONCLUSIONS: Alternating MRI and DM screening at 6-month intervals beginning at age 30 years was identified as a clinically effective approach to applying current guidelines, and was more cost-effective in BRCA1 gene mutation carriers compared with BRCA2 gene mutation carriers.
BACKGROUND: Current clinical guidelines recommend earlier, more intensive breast cancer screening with both magnetic resonance imaging (MRI) and mammography for women with breast cancer susceptibility gene (BRCA) mutations. Unspecified details of screening schedules are a challenge for implementing guidelines. METHODS: A Markov Monte Carlo computer model was used to simulate screening in asymptomatic women who were BRCA1 and BRCA2 mutation carriers. Three dual-modality strategies were compared with digital mammography (DM) alone: 1) DM and MRI alternating at 6-month intervals beginning at age 25 years (Alt25), 2) annual MRI beginning at age 25 years with alternating DM added at age 30 years (MRI25/Alt30), and 3) DM and MRI alternating at 6-month intervals beginning at age 30 years (Alt30). Primary outcomes were quality-adjusted life years (QALYs), lifetime costs (in 2010 US dollars), and incremental cost-effectiveness (dollars per QALY gained). Additional outcomes included potential harms of screening, and lifetime costs stratified into component categories (screening and diagnosis, treatment, mortality, and patient time costs). RESULTS: All 3 dual-modality screening strategies increased QALYs and costs. Alt30 screening had the lowest incremental costs per additional QALY gained (BRCA1, $74,200 per QALY; BRCA2, $215,700 per QALY). False-positive test results increased substantially with dual-modality screening and occurred more frequently in BRCA2 carriers. Downstream savings in both breast cancer treatment and mortality costs were outweighed by increases in up-front screening and diagnosis costs. The results were influenced most by estimates of breast cancer risk and MRI costs. CONCLUSIONS: Alternating MRI and DM screening at 6-month intervals beginning at age 30 years was identified as a clinically effective approach to applying current guidelines, and was more cost-effective in BRCA1 gene mutation carriers compared with BRCA2 gene mutation carriers.
Authors: Robert D Rosenberg; Bonnie C Yankaskas; Linn A Abraham; Edward A Sickles; Constance D Lehman; Berta M Geller; Patricia A Carney; Karla Kerlikowske; Diana S M Buist; Donald L Weaver; William E Barlow; Rachel Ballard-Barbash Journal: Radiology Date: 2006-10 Impact factor: 11.105
Authors: Sylvia K Plevritis; Allison W Kurian; Bronislava M Sigal; Bruce L Daniel; Debra M Ikeda; Frank E Stockdale; Alan M Garber Journal: JAMA Date: 2006-05-24 Impact factor: 56.272
Authors: Etta D Pisano; Constantine Gatsonis; Edward Hendrick; Martin Yaffe; Janet K Baum; Suddhasatta Acharyya; Emily F Conant; Laurie L Fajardo; Lawrence Bassett; Carl D'Orsi; Roberta Jong; Murray Rebner Journal: N Engl J Med Date: 2005-09-16 Impact factor: 91.245
Authors: Allison W Kurian; Rebecca Newton Thompson; Allison F Gaw; Sally Arai; Rafael Ortiz; Alan M Garber Journal: J Clin Oncol Date: 2007-02-20 Impact factor: 44.544
Authors: Edward A Sickles; Diana L Miglioretti; Rachel Ballard-Barbash; Berta M Geller; Jessica W T Leung; Robert D Rosenberg; Rebecca Smith-Bindman; Bonnie C Yankaskas Journal: Radiology Date: 2005-06 Impact factor: 11.105
Authors: M O Leach; C R M Boggis; A K Dixon; D F Easton; R A Eeles; D G R Evans; F J Gilbert; I Griebsch; R J C Hoff; P Kessar; S R Lakhani; S M Moss; A Nerurkar; A R Padhani; L J Pointon; D Thompson; R M L Warren Journal: Lancet Date: 2005 May 21-27 Impact factor: 79.321
Authors: Diana L Lam; Pari V Pandharipande; Janie M Lee; Constance D Lehman; Christoph I Lee Journal: AJR Am J Roentgenol Date: 2014-11 Impact factor: 3.959
Authors: Friedhelm Meier; Anke Harney; Kerstin Rhiem; Silke Neusser; Anja Neumann; Matthias Braun; Jürgen Wasem; Stefan Huster; Peter Dabrock; Rita Katharina Schmutzler Journal: Recent Results Cancer Res Date: 2021
Authors: Shanna L Gustafson; Victoria M Raymond; Monica L Marvin; Tobias Else; Erika Koeppe; Elena M Stoffel; Jessica N Everett Journal: Fam Cancer Date: 2015-03 Impact factor: 2.375
Authors: Dana Madorsky-Feldman; Miri Sklair-Levy; Tamar Perri; Yael Laitman; Shani Paluch-Shimon; Rita Schmutzler; Kerstin Rhiem; Jenny Lester; Beth Y Karlan; Christian F Singer; Tom Van Maerken; Kathleen Claes; Joan Brunet; Angel Izquierdo; Alex Teulé; Jong Won Lee; Sung-Won Kim; Banu Arun; Anna Jakubowska; Jan Lubinski; Katherine Tucker; Nicola K Poplawski; Liliana Varesco; Luigina Ada Bonelli; Saundra S Buys; Gillian Mitchell; Marc Tischkowitz; Anne-Marie Gerdes; Caroline Seynaeve; Mark Robson; Ava Kwong; Nadine Tung; Nalven Tessa; Susan M Domchek; Andrew K Godwin; Johanna Rantala; Brita Arver; Eitan Friedman Journal: Breast Cancer Res Treat Date: 2016-04-27 Impact factor: 4.872